SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

The Lancet
Nov 14, 2020 Volume 396 Number 10262 p1535-1606, e83-e88
https://www.thelancet.com/journals/lancet/issue/current

 

Review
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Gregory A Poland, Inna G Ovsyannikova, Richard B Kennedy
Summary
Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.